Your browser doesn't support javascript.
loading
Predictors of low and very low bone mineral density in long-term childhood acute lymphoblastic leukemia survivors: Toward personalized risk prediction.
Nadeau, Geneviève; Samoilenko, Mariia; Fiscaletti, Melissa; Veilleux, Louis-Nicolas; Curnier, Daniel; Laverdière, Caroline; Sinnett, Daniel; Krajinovic, Maja; Lefebvre, Geneviève; Alos, Nathalie.
Afiliação
  • Nadeau G; CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada.
  • Samoilenko M; Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Fiscaletti M; Division of Endocrinology, Sainte-Justine University Hospital Centre, Montreal, Quebec, Canada.
  • Veilleux LN; CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada.
  • Curnier D; CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada.
  • Laverdière C; Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Sinnett D; Montreal Shriners Hospital for Children, Montreal, Quebec, Canada.
  • Krajinovic M; CHU Sainte-Justine Research Centre, University of Montreal, Montreal, Quebec, Canada.
  • Lefebvre G; Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
  • Alos N; School of Kinesiology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Pediatr Blood Cancer ; 71(8): e31047, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38736190
ABSTRACT

BACKGROUND:

Cohorts of childhood acute lymphoblastic leukemia (cALL) survivors reaching adulthood are increasing. Approximately 30% of survivors meet criteria for low bone mineral density (BMD) 10 years after diagnosis. We investigated risk factors for low BMD in long-term cALL survivors.

METHODS:

We recruited 245 cALL survivors from the PETALE (Prévenir les effets tardifs des traitements de la leucémie aiguë lymphoblastique chez l'enfant) cohort, who were treated with the Dana Farber Cancer Institute protocols, did not experience disease relapse or hematopoietic stem cell transplants, and presented with more than 5 years of event-free survival. Median time since diagnosis was 15.1 years.

RESULTS:

Prevalence of low DXA-derived BMD (Z-score ≤-1) ranged between 21.9% and 25.3%, depending on site (lumbar spine (LS-BMD), femoral neck (FN-BMD), and total body (TB-BMD), and between 3.7% and 5.8% for very low BMD (Z-score ≤-2). Males had a higher prevalence of low BMD than females for all three outcomes (26%-32% vs. 18%-21%), and male sex acted as a significant risk factor for low BMD in all models. Treatment-related factors such as cumulative glucocorticoid (GC) doses and cranial radiation therapy (CRT) were associated with lower BMDs in the full cohort and in females at the FN-BMD site.

CONCLUSION:

Low and very low BMD is more prevalent in male cALL survivors. Male sex, high cumulative GC doses, CRT, risk group, and low body mass index (BMI) were identified as risk factors for low BMD. A longer follow-up of BMD through time in these survivors is needed to establish if low BMD will translate into a higher risk for fragility fractures through adulthood.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Densidade Óssea / Leucemia-Linfoma Linfoblástico de Células Precursoras / Sobreviventes de Câncer Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Densidade Óssea / Leucemia-Linfoma Linfoblástico de Células Precursoras / Sobreviventes de Câncer Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article